Soleno Therapeutics

SOLENO THERAPEUTICS INC

Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.

What Happened

News

Price Target

Markets

Analyst Ratings

Trading Ideas

BILL

CRWD

PLNT

SAIA

SLNO

STLD

TSLA

TTGT

Tesla To $455? Here Are 10 Top Analyst Forecasts For Monday

Soleno Therapeutics (SLNO)

Movers

Soleno Therapeutics, Inc. (NASDAQ: SLNO) shares are trading higher Thursday after the company announced it secured FDA approval for its first commercial drug, Vykat XR (diazoxide choline) extended-release tablets. 

Soleno Shares Are Up Today: What&#39;s Going On?

Macro,View,Of,Stacks,Of,Gold,Bars

Earnings

Equities

Eurozone

Commodities

Intraday Update

AUUD

DRMA

GTEC

Gold Gains Over 1%; TD SYNNEX Shares Plunge After Downbeat Results

Soleno Therapeutics Inc

Management

Press Releases

Soleno Therapeutics Announces the Passing of Former Chairman Ernest Mario, Ph.D.

Soleno Therapeutics to Participate in Upcoming November Investor Conferences

Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

Health Care

Soleno Therapeutics Announces Oral Presentations featuring Diazoxide Choline Extended-Release (DCCR) Tablets in Prader-Willi Syndrome at ESPE 2024

Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference

Financing

Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC

Soleno Therapeutics to Participate in Upcoming February Investor Conferences

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Amicus Therapeutics

Immunovant

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Metsera

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

HC Wainwright & Co.

Stifel

Guggenheim

Laidlaw & Co.

Baird

Comments

Soleno Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga